MorphoSys to Advance Pipeline, Platform Through Up-to-$150M U.S. IPO

MorphoSys plans to raise up to $150 million through an initial public offering (IPO) of its American depositary shares (ADSs), with the goals of developing and commercializing its lead product candidate, the blood cancer treatment MOR208, as well as advancing two other pipeline candidates and its tech platforms.Headquartered in Planegg, Germany, MorphoSys is already a public company in Europe, where its shares trade on the Prime Standard Segment of the Börse Frankfurt (Frankfurt Stock Excha